NEW
YORK, Feb. 1, 2024 /PRNewswire/
-- Immunic, Inc. (Nasdaq: IMUX), a
biotechnology company developing a clinical pipeline of orally
administered, small molecule therapies for chronic inflammatory and
autoimmune diseases, today announced participation in the following
investor and scientific conferences in February:
- February 8: BioCapital Europe
2024. Daniel Vitt, Ph.D.,
Chief Executive Officer and President of Immunic, and Jessica Breu, Vice President Investor Relations
and Communications, will attend this conference in Amsterdam and host one-on-one investor
meetings. To schedule a meeting, please use the BioCapital
conference portal or contact Jessica
Breu at: jessica.breu@imux.com.
- February 29 – March 2: ACTRIMS Forum 2024. Two abstracts
have been accepted for poster presentations at this meeting in
West Palm Beach, FL. The poster
presentations will be accessible on the "Events and Presentations"
section of Immunic's website at:
https://ir.imux.com/events-and-presentations.
- Poster Title: Impact of Vidofludimus Calcium on Serum
Neurofilament in Progressive MS: Data from the CALLIPER Interim
Analysis
- Presenting Author: Robert J.
Fox, MD, Staff Neurologist, Mellen Center for Multiple
Sclerosis, Vice-Chair for Research, Neurological Institute,
Cleveland Clinic, Cleveland,
Ohio
- Abstract Number: 509
- Poster Number: P044
- Poster Session: 1
- Date: Thursday, February 29,
2024
- Time: 6:00 – 7:30 pm
ET
- Poster Title: May Vidofludimus Calcium Potentially be
Used to Reduce Fatigue in Multiple Sclerosis by Blocking EBV
Reactivation?
- Presenting Author: Dr. Alexandra
Herrmann, Manager Translational Pharmacology, Immunic
- Abstract Number: 6
- Poster Number: P271
- Poster Session: 2
- Date: Friday, March 1,
2024
- Time: 6:00 – 7:30 pm
ET
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a biotechnology company developing
a clinical pipeline of orally administered, small molecule
therapies for chronic inflammatory and autoimmune diseases. The
company's lead development program, vidofludimus calcium (IMU-838),
is currently in phase 3 and phase 2 clinical trials for the
treatment of relapsing and progressive multiple sclerosis,
respectively, and has shown therapeutic activity in phase 2
clinical trials in patients suffering from relapsing-remitting
multiple sclerosis, progressive multiple sclerosis and
moderate-to-severe ulcerative colitis. Vidofludimus calcium
combines neuroprotective effects, through its mechanism as a
first-in-class nuclear receptor related 1 (Nurr1) activator, with
additional anti-inflammatory and anti-viral effects, by selectively
inhibiting the enzyme dihydroorotate dehydrogenase (DHODH).
IMU-856, which targets the protein Sirtuin 6 (SIRT6), is intended
to restore intestinal barrier function and regenerate bowel
epithelium, which could potentially be applicable in numerous
gastrointestinal diseases, such as celiac disease, for which it is
currently in preparations for a phase 2 clinical trial. IMU-381,
which currently is in preclinical testing, is a next generation
molecule being developed to specifically address the needs of
gastrointestinal diseases. For further information, please visit:
www.imux.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains "forward-looking
statements" that involve substantial risks and uncertainties for
purposes of the safe harbor provided by the Private Securities
Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release
regarding strategy, future operations, future financial position,
future revenue, projected expenses, sufficiency of cash, expected
timing, development and results of clinical trials, prospects,
plans and objectives of management are forward-looking statements.
Examples of such statements include, but are not limited to,
statements relating to management's and employee's participation in
investor and scientific conferences. Immunic may not actually
achieve the plans, carry out the intentions or meet the
expectations or projections disclosed in the forward-looking
statements and you should not place undue reliance on these
forward-looking statements. Such statements are based on
management's current expectations and involve substantial risks and
uncertainties. Actual results and performance could differ
materially from those projected in the forward-looking statements
as a result of many factors, including, without limitation, the
COVID-19 pandemic, increasing inflation, impacts of the
Ukraine – Russia conflict and the conflict in the
Middle East on planned and ongoing
clinical trials, risks and uncertainties associated with the
ability to project future cash utilization and reserves needed for
contingent future liabilities and business operations, the
availability of sufficient financial and other resources to meet
business objectives and operational requirements, the fact that the
results of earlier preclinical studies and clinical trials may not
be predictive of future clinical trial results, the protection and
market exclusivity provided by Immunic's intellectual property,
risks related to the drug development and the regulatory approval
process and the impact of competitive products and technological
changes. A further list and descriptions of these risks,
uncertainties and other factors can be found in the section
captioned "Risk Factors," in the company's Annual Report on Form
10-K for the fiscal year ended December 31,
2022, filed with the SEC on February
23, 2023, and in the company's subsequent filings with the
Securities and Exchange Commission. Copies of these filings are
available online at www.sec.gov or ir.imux.com/sec-filings. Any
forward-looking statement made in this release speaks only as of
the date of this release. Immunic disclaims any intent or
obligation to update these forward-looking statements to reflect
events or circumstances that exist after the date on which they
were made. Immunic expressly disclaims all liability in respect to
actions taken or not taken based on any or all the contents of this
press release.
Contact Information
Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 633 7790
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 617 974 8659
kaplan@kogspr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/immunic-to-participate-in-investor-and-scientific-conferences-in-february-302050283.html
SOURCE Immunic, Inc.